GSK Deal, Fevertree Up, Seraphim Soars
Failed to add items
Add to cart failed.
Add to wishlist failed.
Remove from wishlist failed.
Follow podcast failed
Unfollow podcast failed
GSK Deal, Fevertree Up, Seraphim Soars
-
Narrated by:
-
Written by:
Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- GSK agreed to buy Nuvalent Inc. in a deal valued at $10.6 billion (7.9 billion pounds), adding a biotech firm that’s developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise.
- Fever-Tree shares rise as much 8.2% to the highest in a month after the company said it was on track to meet expectations and extended its buyback program.
- Seraphim Space Investment Trust shares rise as much as 26%, their biggest jump in almost three years, after the fund said the fair value of Iceye, its largest holding, had doubled after a funding round. Shares of Molten Ventures, which also invests in Iceye, gain as much as 12%.
See omnystudio.com/listener for privacy information.